Back to Results

A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of PSB205 in Patients with Relapsed/Refractory Solid Tumors

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Patient must be eligible for cisplatin treatment

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Breelyn Wilky,  MD

Breelyn Wilky, MD

Study ID

Protocol Number: 19-1069

More information available at ClinicalTrials.gov: NCT03986606

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers